CagriSema
Cagrilintide + Semaglutide combination
Powerful semaglutide + cagrilintide combination
Fat Loss ★ 80
Half-life
~1 week (both components)
Cycle
Long-term maintenance, same pattern as semaglutide.
Storage
Lyophilized: refrigerated 2-8°C. After reconstitution: 2-8°C, 28 days.
Research
Phase 3 (REDEFINE program), expected approval 2025-2026
About
Novo Nordisk's Phase 3 combination of cagrilintide (long-acting amylin analog) and semaglutide. Aimed at exceeding tirzepatide for weight loss.
Mechanism
Dual action: cagrilintide reduces appetite via amylin receptors, semaglutide activates GLP-1.
Dosage
0.25 mg + 0.25 mg
1x per week (4-week titration)
0102030405060708090100
Draw to 10 units on a U-100 insulin syringe
5 mg + 5 mg · 2 mL BAC
Route
Subcutaneous (SubQ)
Duration
Long-term
When to take: Same weekday each week. Best in the morning or evening.
Reconstitution
Vial size (mg): 5 mg + 5 mg · BAC water (mL): 2 mL · Concentration: 2.5 mg/mL each
The clinical form is a pre-mixed pen. Compounded forms are blended together.
Benefits
- Potentially largest weight loss among GLP-1 drugs
- Smoother appetite control (dual mechanism)
- Improved glycemic control
- Less nausea than pure semaglutide
Side effects
- Nausea and vomiting (common initially)
- Diarrhea or constipation
- Headache
- Possible pancreatitis (rare)
Gender notes
Same dose as general protocol.
Cautions
- Pregnancy and breastfeeding
- History of pancreatitis
- Medullary thyroid carcinoma (MEN2)
- Severe gastroparesis
Research
- Frias et al: CagriSema phase 2 in T2D
The Lancet · 2023
Phase 2 in type 2 diabetes: 15.6% weight loss.